BMS CA224-098, RELATIVITY 098 (Melanoma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if combining 2 drugs (relatlimab + nivolumab) is more effective than using nivolumab on its own to prevent a recurrence of melanoma. Currently, using nivolumab on its own is the standard treatment to prevent melanoma from coming back after it has been removed by surgery.

What is the Condition Being Studied?

Melanoma

Who Can Participate in the Study?

Adults ages 18+ who:
- Are diagnosed with stage III or 4 melanoma
- Have had their tumor(s) completely removed

For more information about who can join this study, please contact the study team at ivy.belskie@duke.edu.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Be randomly assigned (like a coin flip) to 1 of 2 groups
-- One group will get relatlimab + nivolumab after surgery
-- The other group will get nivolumab on its own after surgery
- Both groups will get dosed every 4 weeks by intravenous (IV) infusion for up to 1 year

Study Details

Full Title
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00109246
NCT: NCT05002569
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698